UNSPSC 51461513: Gumplant

This classification denotes a natural product which US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifiers C08B09D8UJ (whole) and AOK8NJ16UX (leaf), which the Integrated Taxonomic Information System classifies under Taxonomic Serial Number 37451 as a member of Kingdom Plantae, Subkingdom Viridaeplantae, Infrakingdom Streptophyta, Division Tracheophyta, Subdivision Spermatophytina, Infradivision Angiospermae, Class Magnoliopsida, Superorder Asteranae, Order Asterales, Family Asteraceae (sunflowers, tournesols), Genus Grindelia Willd., commonly known as GUMWEED or as here, GUMPLANT.

Grindelia hirsutula bears the USDA PLANTS Database Identifier GRHI. European Medicines Agency schedules grindelia in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14025MIG. SMILES: NONE.

UNSPSC 51461513 Gumplant, a Commodity code, encompasses generic and over-the-counter pharmaceutical products supplied through state and local cooperative purchasing agreements and institutional procurement channels. Based on recent solicitation activity, state and local governments buy standardized pharmaceutical inventory—including generic multi-source drugs and OTC items—through centralized cooperative contracts that establish pricing, product specifications, supply-chain credentials, and distribution relationships with licensed wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administers purchasing for state agencies and participating local jurisdictions across multiple states, and similar cooperative vehicles likely drive comparable procurement at the county and municipal level, though the recent-opportunities block reflects limited visibility into the full base of issuing bodies currently sourcing under this code.

MMCAP's January 2026 RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, due March 26, 2026) is the most recent signaled opportunity under this code and frames the current market: vendors must supply through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC), maintain cGMP and Drug Supply Chain Security Act compliance, carry minimum insurance coverage of $5 million general liability and $2 million network security liability, and submit detailed product data (NDC codes, SKUs, UPCs, strength, dosage form, packaging) keyed to marketplace availability by May 15, 2026. Contract awards will be effective July 1, 2026, with a two-year term and optional extensions; pricing is weighted at 75 percent of evaluation, with fixed pricing, EDI capability, and administrative-fee compliance constituting the balance. The procurement does not identify set-aside restrictions in available documentation. Geographic activity centers on Minnesota and Oregon as signaled participants; however, the source provides insufficient recent opportunity records to characterize the broader state and local geographic spread or to identify repeat buyers beyond MMCAP.